12,372 trials
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at…
Pompe Disease (Late-onset)
Primary: Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD) — 21.31; 7.10 meter — p=0.048
Respiratory Syncytial Virus Prevention
Primary: Geometric Mean Titers (GMTs) of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) 14 Days Post Vaccination — 5054; 4836…
Agitation Associated With Bipolar Disorder · Agitation,Psychomotor · Bipolar Disorder
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 18.0; 18.0; 17.9; -10.4 score on a scale — p=<0.0001
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 58; 29; 43; 45 Participants
Asthma · Obesity
Primary: Asthma Control Questionnaire (Juniper) — 1.13; 1.08; -0.08; -0.09 score on a scale — p=0.05
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
Diabetes Mellitus
Primary: Change in Hemoglobin A1c (HbA1c) — -3.18; -3.00 percentage of HbA1c
Helicobacter Pylori
Primary: Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment — 86.8; 86.7 percentage of participants — p==0.0009
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs) — 10; 1 Participants
Respiratory Syncytial Virus Prevention
Primary: Geometric Mean Titers (GMTs) of Prefusion F-protein (preF) Antibodies as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) 14 Days Post Vaccination — 4277; 4121…
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009
Glabellar Frown Lines (GL) · Lateral Canthal Lines (LCL)
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown — 0; 75; 78 Participants…
Intraoperative Complication · Malignant Female Reproductive System Neoplasm · Pain
Primary: Relative Pain Scores, as Measured by the Pain Numeric Rating Scale (NRS) — 3.87; 4.95 score on a scale